Anaemia management in cardio renal disease

Journal of Renal Care

Volumn 36, Issue SUPPL. 1, 2010, Pages 86-96

  Silverberg, Donald S ^a   Wexler, Dov ^a   Iaina, Adrian ^a   Schwartz, Doron ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anaemia; Erythropoietin; Heart failure; Iron; Renal failure

Indexed keywords

ANTIANEMIC AGENT; CYTOKINE; DRUG DERIVATIVE; ERYTHROPOIETIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD; CARDIOVERSION; CHRONIC KIDNEY FAILURE; HEART FAILURE; HUMAN; IRON DEFICIENCY ANEMIA; NURSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ANEMIA; ANEMIA, IRON-DEFICIENCY; CYTOKINES; ELECTRIC COUNTERSHOCK; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77952572352     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2010.00164.x     Document Type: Article

References (99)

1. Abraham W.T., Klaphotz M., Anand I. et al 2007). Safety and efficacy of darbepoetin alpha treatment in anemic patients with symptomatic heart failure: a pooled analysis of 2 randomized, double blind placebo-controlled trials. European Heart Journal 27 (Suppl 166.
2. Abramov D., Cohen R.S., Katz S.D. et al 2008). Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fraction. American Journal of Cardiology 102, 1069 1072.
3. Adlbrecht C, Kommata S., Hulsmann M. et al 2009). Chronic heart failure leads to an expanded plasma volume and pseudo, but does not lead to a reduction in the body's red cell volume. European Heart Journal 29, 2343 2350.
4. Anand I.S. (2008). Anemia and chronic heart failure. Journal of the American College of Cardiology 52, 501 511.
5. Androne A.S., Katz S.D., Lund L. et al 2003). Hemodilution is common in patients with advanced heart failure. Circulation 107, 226 229.
6. Anker S., Comin-Colet J., Filippatos G. et al 2009a). Rationale and design of Ferinject assessment in patients with iron deficiency and chronic heart failure (FAIR-HF) study: a randomized placebo-controlled study of intravenous iron supplementation in patients with and without anemia. European Journal of Heart Failure 11, 1084 1091.
7. Anker S.D., Comin Colet J., Fillipatos G. et al 2009b). Ferric carboxy-maltose in patients with heart failure and iron deficiency. New England Journal of Medicine 361, 2436 2448.
8. Arcasoy M.O. (2008). The non-haematopoietic biological effects of erythropoietin. British Journal of Hematology 141, 14 31.
9. Ashby D.R., Gale D.P., Busbridge M. et al 2009). Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney International 75, 976 981.
10. Bansal N., Tighiouart H., Weiner D. et al 2007). Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology 99, 1137 1142.
11. Bennett C.L., Silver S.M., Djulbegovic B.T. et al 2008). Venous throm-boembolism and mortality associated with Recombinant Erythropoietin and Darbepoetin administration for the treatment of cancer-associated anemia. Journal of the American Medical Association 299, 914 924.
12. Berria R., Glass L., Mahenkali A. et al 2007). Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Journal of Clinical Pharmacology and Therapeutics 82, 275 281.
13. Besarab A., Horl W.A., Silverberg D. (2009). Iron metabolism, iron deficiency, thrombocytosis and the cardiorenal anemia syndrome. Oncologist 14 (Suppl 1 22 33.
14. Beutler E. (2002). History of iron in medicine. Blood Cells, Molecules and Diseases 29, 297 308.
15. Beutler E., Larsh S.E., Guerney C.W. (1960). Iron therapy in chronically fatigued non anemic women: a double-blind controlled study. Annals of Internal Medicine 52, 378 393.
16. Beutler E. Waalen J. (2006). The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration. Blood 107, 1747 1750.
17. Bishu K. Agarwal R. (2006). Acute injury with intravenous iron and concerns regarding long-term safety. Clinical Journal of the American Society of Nephrology 1 (Suppl 1 S19 S23.
18. Boerrigter G., Costello-Boerrigter L.C., Abraham W.T. et al 2008). Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular function. Journal of Cardiac Failure 14, 539 546.
19. Bolger A.P., Bartlett F.P., Penston H.S. et al 2006). Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. Journal of the American College of Cardiology 48, 1225 1227.
20. Brownlie T., Untermohlen V., Hinton P.S. et al (2002). Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. American Journal of Clinical Nutrition 75, 733 742.
21. Canario-Almeida F., Azevedo L, Ferreira F. et al 2009). Is there a role to erythropoiesis-stimulating proteins in the treatment of anemic chronic heart failure patients: a meta-analysis of randomized controlled studies. European Heart Journal 30 (Suppl) Abstract P2491.
22. Comin-Colet J., Ruiz S., Cladellas M. et al 2009). A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and Cardio Renal Anemia Syndrome: influence on neurohormonal activation and clinical outcomes. Journal of Cardiac Failure 15, 727 735.
23. Coyne D.W., Kapoian T., Suki W. et al 2007). Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV Iron with elevated ferritin (DRIVE) study. Journal of the American Society of Nephrology 18, 975 984.
24. Dahl N.V., Henry D.H., Coyne D.W. (2008). Thrombosis with erythropoietic stimulating agents- Does iron deficient erythropoiesis play a role? Seminars in Dialysis 21, 210 211.
25. Darze E.S., Latado A.S., Guimaraes A.G. et al 2005). Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 128, 2576 2580.
26. Dong F., Zhang X., Culver B., et al 2005). Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrosome C release: involvement of nitric oxide synthase and protein tyrosine nitration. Clinical Science 109, 277 286.
27. Drakos S., Anastasiou-Nana M., Kaldara E. et al 2008). In advanced heart failure intravenous iron is the preferred treatment of iron deficiency anemia. European Journal of Heart Failure (Suppl 7 192.
28. Dunlay S.D., Weston S.A., Redfield M.M. et al 2008). Anemia and heart failure: a community study. American Journal of Medicine 121, 726 732.
29. Eschbach J.W., Abdulhadi M.H., Browne J.K. et al 1989). Recombinant human erythropoietin in anemic patients with end-stage renal disease. Annals of Internal Medicine 111, 992 1000.
30. Feldman H.I., Joffe M., Robinson B. et al 2004). Administration of parenteral iron and mortality among hemodialysis patients. Journal of the American Society of Nephrology 15, 1623 1632.
31. Fox K., Borer J.S., Camm J. et al 2007). Resting heart rate in cardiovascular disease. Journal of the American College of Cardiology 50, 823 830.
32. Ghali J.K. (2009). Anemia and heart failure. Current Opinion in Cardiology 24, 172 178.
33. Ghali J., Anand I., Abraham W.T. et al 2008). Randomized double blind trial of Darbepoetin Alpha treatment in patients with symptomatic heart failure and anemia. Circulation 117, 526 535.
34. Gotloib L, Silverberg D.S., Fudin R. et al 2006). Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. Journal of Nephrology 19, 161 167.
35. Grzeslo, Jankowska E.A., Witkowski J. et al 2006). Iron deficiency is a common finding in patients with stable chronic heart failure. European Journal of Heart Failure (Suppl 5 132.
36. Groenwald H.F, Januzzi J.L., Damman K. et al 2008). Anemia and mortality in heart failure patients: a systematic review and meta-analysis. Journal of the American College of Cardiology 52, 818 827.
37. Haas J.D. Brownlie T. (2001). Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. Journal of Nutrition 131, 676S 688S.
38. He S-W. Wang L-X. (2009). The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. CHF 15, 123 130.
39. Hutchinson C., Geissler C.A., Powell J.J. et al 2007). Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56, 1291 1295.
40. Hyatt T.C., Phadke R.P., Hunter G.R. et al 2009). Insulin sensitivity in African Americans and white women. Obesity 17, 276 282.
41. Jackson C.E., Solomon S.D., Gerstein H.C. et al 2009). Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374, 543 550.
42. Kalantar-Zadeh K., Regidor D.L., McAllister C.J. et al 2005). Time-dependent associations between iron and mortality in hemodialysis patients. Journal of the American Society of Nephrology 16, 3070 3080.
43. Kapoian T., O'Mara M.D., Singh A.K. et al 2008). Ferric gluconate reduces erythropoietin requirements in hemodialysis patients with elevated ferritin. Journal of the American Society of Nephrology 19, 372 379.
44. Katodritou E., Zervas K., Terpos E. et al 2008). Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment related anaemia: the need for predictors of effectiveness has not abated. British Journal of Hematology 142, 3 10.
45. Kazory A. Ross E.A. (2009). Anemia: the point of convergence or divergence for kidney disease and heart failure? Journal of the American College of Cardiology 53, 639 647.
46. Khan W., Deepak S.M., Coppinger T. et al 2006). Beta blocker treatment is associated with improvement in renal function and anemia in patients with heart failure. Heart 92, 1856 1857.
47. Klapholz M., Abraham W.T., Ghali J.K. et al 2009). The safety and tolerability of darbepoetin alfa in patients with and symptomatic heart failure. European Journal of Heart Failure 11, 1071 1077.
48. Kourea K., Parissis J.T., Farmakis D. et al 2008). Effects of darbepoetin-alfa on quality of life and emotional stress in anemic patients with chronic heart failure. European Journal of Cardiovascular and Preventive Rehabilitation 15, 365 369.
49. Kovesdy C.P., Estrada W., Ahmadzadeh S., et al 2009). Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clinical Journal of the American Society of Nephrology 4, 435 441.
50. Krapf R. Hulter H.N. (2009). Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clinical Journal of the American Society of Nephrology 4, 470 480.
51. Kuo K.L., Hung S.C., Wei Y.H. et al 2008). Intravenous iron exacerbates oxidative DANN damage in peripheral blood lymphocytes in chronic hemodialysis patients. Journal of the American Society of Nephrology 19, 1817 1826.
52. Lebel M., Kingma I., Grose J.H. (1998). Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. Journal of the American Society of Nephrology 9, 97 104.
53. Levy P.S., Kim S.J., Eckel P.K. et al 1993). Limit to cardiac compensation during acute isovolemic hemodilution: inflence of coronary stenosis. American Journal of Physiology 265, H340 H349.
54. Littlewood T.J. (2008). Normalization of hemoglobin in patients with CKD may cause harm: but what is the mechanism? American Journal of Kidney Diseases 52, 642 644.
55. Logeart D., Gueffet J.P., Rouzet F. et al 2009). Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a plot study. European Journal of Heart Failure 11, 53 57.
56. Lopez-Gomez J.M., Portoles J.M., Aljama P. (2008). Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney International 74 (Suppl 11 S75 S81.
57. Maiese K., Li F. Chong Z. (2005). New avenues of exploration for erythropoietin. Journal of the American Medical Association 293, 90 95.
58. McMurray J.J.V, Anand I.S., Diaz R. et al 2009). Design of the reduction of events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anemia correction morbidity-mortality trial. European Journal of Heart Failure 11, 795 801.
59. Mancini D.M., Katz S.D., Lang C.C., et al 2003). Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294 299.
60. Mircescu G., Garneata L, Capusa C. et al 2006). Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients. Nephrology Dialysis Transplantation 21, 120 124.
61. Murphy C.L., Fitzimmons R.J., Jardine A.J. et al 2007). Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anemia. European Journal of Heart Failure 61, 103.
62. Nagababu E., Gulyani S., Earley C.J. et al 2008). Iron-deficiency enhances red cell oxidative stress. Free Radical Research 42, 824 829.
63. Naito Y., Tsujino T., Matsumoto M. et al 2009). Adaptive response of the heart to long term anemia induced by iron deficiency. American Journal of Physiology Heart Circulation Physiology 296, H585 H593.
64. Nanas J.N., Matsouka C, Karageorgopoulos D. et al 2006). Etiology of anemia in patients with advanced heart failure. Journal of the American College of Cardiology 48, 2485 2489.
65. Nemeth E. (2008). Iron regulation and erythropoiesis. Current Opinion in Hematology 15, 169 175.
66. Ngo K., Kotecha D., Walters J. et al 2009). Erythropoiesis-stimulating agents for anemia in chronic heart failure patients. Cochrane Database Systematic Reviews. CD007613.
67. Okonko D.O., Grzeslo A., Witkowski T. et al 2008). Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. Journal of the American College of Cardiology 51, 103 112.
68. Opasich C., Cazzola M., Scelsi L. et al 2005). Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of in patients with chronic heart failure. European Heart Journal 26, 2232 2237.
69. Owan T.E., Hodge D.O., Herges R.M. et al 2006). Secular trends in renal dysfunction in hospitalized heart failure patients. Journal of Cardiac Failure 12, 257 262.
70. Palazzuoli A., Silverberg D.S., Iovine F. et al 2006). Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. American Heart Journal 152, 1096e9 15.
71. Palazzuoli A., Silverberg D.S., Calbro A. et al 2009). Beta-erythropoi-etin effects on ventricular remodelling, left and right systolic function, pulmonary pressure and hospitalizations in patients with heart failure and anemia. Journal of Cardiovascular Pharmacology 53, 462 467.
72. Parissis J.T., Kourea K., Andreadou I. et al 2009). Effects of Darbepoetin alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology 103, 1134 1138.
73. Pollak V.E., Lorch J.A., Shukla R. et al 2009). The importance of iron in long-term survival of maintenace hemodialysis patients treated with epoetin-alpha and intravenous iron: analysis of 9. 5 years of prospectively collected data. BMC Nephrology 10, 6.
74. Ponikowski P., Anker S.D., Szachniewicz J. et al 2007). Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. Journal of the American College of Cardiology 49, 753 762.
75. Rastogi S., Sharov V.G., Mishra S. et al 2008). Darbepoetin alpha prevents progressive left ventricular dysfunction and remodeling in non-anemic dogs with heart failure. American Journal of Physiology Heart Circulation Physiology 295, H2475 H2482.
76. Rizzo J.D., Somerfield M.R., Hagerty K.L. et al 2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111, 25 41.
77. Rozen-Zvi B., Gafter-Gvili A., Paul M. et al 2008). Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. American Journal of Kidney Diseases 52, 897 906.
78. Silverberg D.S., Wexler D., Blum M. et al 2000). The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology 35, 1737 1744.
79. Silverberg D.S., Wexler D., Blum M. et al 2005). Effects of treatment with EPO beta on outcomes in patients with anemia and chronic renal failure. Kidney Blood Press Research 28, 41 47.
80. Silverberg D.S., Wexler D., Iaina A. et al 2008). The role of patients with congestive heart failure: a short review. European Journal of Heart Failure 10, 819 823.
81. Silverberg D.S., Wexler D., Iaina A. et al 2009). The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clinical and Experimental Nephrology 13, 101 106.
82. Silverberg D.S., Wexler D., Sheps D. et al 2001). The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology 37, 1775 1780.
83. Smilde T.D.J., Damman K., Van Der Harst P. et al 2009). Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure. Clinical Research in Cardiology 98, 121 129.
84. Streja E., Kovesdy C.P., Greenland S. et al 2008). Erythropoietin, iron depletion and thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. American Journal of Kidney Diseases 52, 727 736.
85. Sun Q., Ma J., Rifai N. et al 2008). Excessive body iron stores are not associated with risk of coronary heart disease in women. Journal of Nutrition 138, 2436 2441.
86. Tang Y.D. Katz S.D. (2008). The prevalence of anemia in chronic heart failure and its impact on clinical outcomes. Heart Failure Review 13, 387 392.
87. Tehrani F., Dhesi P., Daneshvar B. et al 2009). Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovascular Drugs and Therapy 23, 511 518.
88. Toblli J., Lombrana A., Duarte P. et al 2007). Intravenous iron reduces NT-pro-BNP in anemic patients with chronic heart failure and renal insufficiency. Journal of the American College of Cardiology 50, 1657 1665.
89. Tuomainen T.P., Punnonen K., Nyyssonen K. et al 1998). Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97, 1461 1466.
90. Usmanov R.I., Zueva E.B., Silverberg D.S. et al 2008). Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. Journal of Nephrology 21, 236 242.
91. Vaisman N., Silverberg D.S., Wexler D. et al 2004). Correction of anemia in patients with congestive heart failure increases resting energy expenditure. Clinical Nutrition 23, 355 361.
92. Van Der Meer P., Groenveld H., Januzzi J.L. et al 2009). Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95, 1309 1314.
93. Van Veldhuisen D.J., Dickstein K., Cohen-Solal A. et al 2007). Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure. European Heart Journal 28, 2208 2216.
94. Van Wyck D.B., Roppolo M. Martinez C.O. 2005). A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD. Kidney International 68, 2846 2856.
95. Vaziri N.D. (2008). Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease. Nature Clinical Practice Nephrology 4, 436 445.
96. Verdon F., Burnand B., Fallab C.L. et al 2003). Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. British Medical Journal 326, 1124 1126.
97. Weiss G. (2008). Iron metabolism in the anemia of chronic disease. Biochimica Biophysica Acta 1790, 682 693.
98. Westenbrink B.D., Visser F.W., Voors A.A. et al 2007). In chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. European Heart Journal 28, 166 171.
99. Zilberman M., Silverberg D.S., Bits I. et al 2007). Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing and improves sleepiness in anemic patients with congestive heart failure. American Heart Journal 154, 870 876.